User profiles for Ahed Makhoul

Ahed Makhoul

Cleveland Clinic Foundation
Verified email at ccf.org
Cited by 58

BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes

…, A Advani, B Przychodzen, A Makhoul… - Leukemia & …, 2019 - Taylor & Francis
To the Editor, The myelodysplastic syndromes (MDS) are a heterogeneous group of
hematologic conditions characterized by dysplastic changes and ineffective hematopoiesis [1]. …

The role of palliative care in COVID-19.

D Sese, A Makhoul, L Hoeksema… - Cleveland Clinic Journal …, 2020 - europepmc.org
In light of the COVID-19 pandemic, many healthcare systems are experiencing an increased
demand for palliative care (PC). To meet this challenge, the PC team at Cleveland Clinic …

[HTML][HTML] A personalized prediction model to risk stratify patients with acute myeloid leukemia (AML) using artificial intelligence

…, H Awada, S Mukherjee, W Walter, S Hutter, A Makhoul… - Blood, 2019 - Elsevier
Background AML is a heterogeneous clonal disorder that is characterized by the accumulation
of complex genomic alterations that affect disease biology and outcomes. Despite …

[HTML][HTML] A personalized prediction model to risk stratify patients with acute myeloid leukemia (AML)

A Nazha, S Mukherjee, K Al-Issa, A Makhoul, V Adema… - Blood, 2017 - Elsevier
AML is a heterogeneous clonal disorder that is characterized by the accumulation of complex
genomic abnormalities that impact disease biology and outcome. Despite significant …

[HTML][HTML] Model heterogeneity in predicting outcomes of patients with myelodysplastic syndromes (MDS)

…, CM Hirsch, AT Gerds, N Abuhadra, A Makhoul… - Blood, 2017 - Elsevier
Background The outcome of MDS patients (pts) is heterogeneous, with some pts living for
years, while others die within a few months of diagnosis. Several prognostic models have …

Response Rates to Methylnaltrexone in Hospitalized Cancer Patients

…, F Fielding, R Lagman, A Makhoul… - American Journal of …, 2023 - journals.sagepub.com
Context: Methylnaltrexone is a peripherally-acting mu-opioid receptor antagonist studied in
both cancer and non-cancer patients with opioid-induced constipation (OIC), but mostly in …

Molecular dissection of normal karyotype acute myeloid leukemia.

…, S Mukherjee, W Walter, S Hutter, A Makhoul… - 2020 - ascopubs.org
7534 Background: Conventional cytogenetics remain one of the most important prognostic
factors in acute myeloid leukemia (AML), though 50-60% of patients (pts) have normal …

Methylnaltrexone for Refractory Opioid-Induced Constipation in Hospitalized Cancer Patients—A Highly Effective Treatment (F415A)

…, F Fielding, RL Lee, A Makhoul… - Journal of Pain and …, 2021 - jpsmjournal.com
Methods We performed a single-center, retrospective chart review of all hospitalized, adult
patients with a cancer diagnosis who received methylnaltrexone from the palliative medicine …

[HTML][HTML] Molecular Characterization of Acute Myeloid Leukemia Patients with Normal Karyotype

…, S Mukherjee, W Walter, S Hutter, A Makhoul… - Blood, 2018 - Elsevier
Background Conventional cytogenetic classification remains one of the most important
prognostic factors in acute myeloid leukemia (AML). Approximately 50-60 % of patients (pts) with …

[HTML][HTML] Patterns of Genomic Associations Can Define Acute Myeloid Leukemia (AML) Phenotype

A Nazha, MA Sekeres, K Al-Issa, A Makhoul, V Adema… - Blood, 2017 - Elsevier
AML can develop after an anteccedent myeloid malignancy (secondary AML [sAML]) or
arise de novo (pAML). Genome sequencing technologies have illuminated the complexity of …